Open Access. Powered by Scholars. Published by Universities.®
Epigenetic therapy;; histone deacetylase inhibitor;; romidepsin;; T-cell;; lymphoma;; chromatin;; histone deacetylase inhibitor;; phase-ii trial;; suberoylanilide;; hydroxamic acid;; therapeutic activities;; depsipeptide fr901228;; dependent apoptosis;; mycosis-fungoides;; sezary-syndrome;; solid tumors;; lung-cancer;; Hematology
Articles 1 - 1 of 1
Full-Text Articles in Hematology
Romidepsin In Peripheral And Cutaneous T-Cell Lymphoma: Mechanistic Implications From Clinical And Correlative Data, S. E. Bates, R. Eisch, A. Ling, D. Rosing, M. Turner, S. Pittaluga, H. M. Prince, M. H. Kirschbaum, S. L. Allen, R. L. Piekarz, +15 Additional Authors
Romidepsin In Peripheral And Cutaneous T-Cell Lymphoma: Mechanistic Implications From Clinical And Correlative Data, S. E. Bates, R. Eisch, A. Ling, D. Rosing, M. Turner, S. Pittaluga, H. M. Prince, M. H. Kirschbaum, S. L. Allen, R. L. Piekarz, +15 Additional Authors
Journal Articles
Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or peripheral T-cell lymphoma (CTCL and PTCL). Here we report data in all patients treated on the National Cancer Institute 1312 trial, demonstrating long-term disease control and the ability to retreat patients relapsing off-therapy. In all, 84 patients with CTCL and 47 with PTCL were enrolled. Responses occurred early, were clinically meaningful and of very long duration in some cases. Notably, patients with PTCL receiving romidepsin as third-line therapy or later had a comparable response rate (32%) of similar duration as the total population (38%). Eight patients …